Media stories about Rockwell Medical (NASDAQ:RMTI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rockwell Medical earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.3633105074281 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s rankings:

Rockwell Medical (RMTI) traded up 1.45% during trading on Friday, reaching $6.29. 168,020 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $7.12 and a 200-day moving average price of $6.92. The firm’s market cap is $325.44 million. Rockwell Medical has a 12 month low of $3.55 and a 12 month high of $8.98.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The firm had revenue of $13.24 million for the quarter, compared to analyst estimates of $13.05 million. Rockwell Medical had a negative return on equity of 42.22% and a negative net margin of 39.68%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. On average, analysts forecast that Rockwell Medical will post ($0.44) earnings per share for the current fiscal year.

Several equities analysts have commented on the stock. BidaskClub raised shares of Rockwell Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Tuesday. Ifs Securities assumed coverage on shares of Rockwell Medical in a research report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 target price on the stock. Finally, ValuEngine downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Four analysts have rated the stock with a sell rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Rockwell Medical currently has an average rating of “Hold” and a consensus price target of $8.38.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Insider Buying and Selling by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with's FREE daily email newsletter.